PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of orphjrdisBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleOrphanet Journal of Rare DiseasesJournal Front Page
 
Orphanet J Rare Dis. 2012; 7(Suppl 2): A1.
Published online Nov 22, 2012. doi:  10.1186/1750-1172-7-S2-A1
PMCID: PMC3504585
State of the art of rare disease activities in Europe: a EUCERD perspective
Ségolène Aymécorresponding author1
1Inserm, US14, Orphanet, Paris, France
corresponding authorCorresponding author.
Ségolène Aymé: segolene.ayme/at/inserm.fr
Supplement
6th European Conference on Rare Diseases and Orphan Products
Kasia Peala and Alice Elliott
This publication (or activity) has been funded with support from the European Union's Health Programme. This material only reflects the views of the author, and funders cannot be held responsible for any use which may be made of the information contained herein.
Conference
6th European Conference on Rare Diseases and Orphan Products
23-25 May 2012
Brussels, Belgium
Two years ago, at the ECRD in Krakow, we were celebrating the recommendation of the Council of Ministers on an action in the field of rare diseases: this recommendation requests that Member States define and implement a plan or a strategy for rare diseases by the end of 2013 and asks the European Commission to establish a EU Committee of Experts in the field of Rare Diseases (EUCERD) as a forum of stakeholders to propose action points at EU level. Two years on, there is enough evidence to judge the outcome of Recommendation which can be qualified as positive despite the economic crisis. The dynamic of action is still impressive (Figure (Figure1).1). The EUCERD has been established and fulfills its mission as expected. The publication of the EUCERD annual report on the state of art of rare disease activities in Europe testifies the many achievements [1]. The EUCERD adopted a set of quality criteria for the designation of centres of expertise for rare diseases at national level. This work served as a basis for the working group on centres of expertise in the framework of the Cross Border Healthcare Directive. All countries are now engaged in the process of elaborating a plan or a strategy for rare diseases (Figure (Figure2).2). The recent developments in genomics now translate into more diagnostic tests for rare diseases. So far over 1,800 rare diseases can be tested in one EU country. Targeted funding for rare diseases has also produced its effects, with more transnational cooperation which translated into the important decision to establish an International Consortium to fund research: the IRDiRC. The Consortium will allow more ambitious goals to be set and achieved faster and it will ease the mobilisation of the critical mass of expertise and resources whilst avoiding overlaps in research. The Regulation on Orphan Medicinal Products is still producing positive effects with currently over 70 products with a marketing authorisation in the EU and many more in development. The Orphanet database became a Joint Action between all Member States, showing the great degree of willingness to provide unified, high-quality information to all EU citizens. Last but not least, patient organisations are increasingly better organised to make their voice heard. Not only is EURORDIS the voice of patients in Europe, but umbrella organisations have been established in most countries (Figure (Figure33).
Figure 1
Figure 1
Emergence of concepts and initiatives surrounding rare diseases in Europe
Figure 2
Figure 2
Current stages of development of national plans or strategies for rare diseases in EU MS (in December 2011).
Figure 3
Figure 3
Countries in Europe with a national alliance for rare disease patient organisations and year founded
References
Articles from Orphanet Journal of Rare Diseases are provided here courtesy of
BioMed Central